Fig. 6.
Distribution of key parameters in training and held-out private evaluation sets (written as test). (A) T2-weighted MRI sequence type (Non-FS: non-fat suppressed, FS: fat suppressed). (B) Tumor response status at mid-therapy (NCR: non-complete response, Other: any combination of complete and non-response of primary and node). (C) Primary gross tumor volume (GTVp) and (D) nodal gross tumor volume (GTVn), both categorized as above or below the dataset median. (E) Human papillomavirus (HPV) status. (F) Tumor anatomic subsite (BOT: base of tongue). (G) T-stage and (H) N-stage as per the eighth edition American Joint Committee on Cancer staging system.
